<Header>
<FileStats>
    <FileName>20161215_10-Q-A_edgar_data_1402785_0001654954-16-004900_1.txt</FileName>
    <GrossFileSize>99830</GrossFileSize>
    <NetFileSize>11763</NetFileSize>
    <ASCII_Embedded_Chars>0</ASCII_Embedded_Chars>
    <HTML_Chars>76056</HTML_Chars>
    <XBRL_Chars>0</XBRL_Chars>
    <XML_Chars>0</XML_Chars>
    <N_Tables>4</N_Tables>
    <N_Exhibits>2</N_Exhibits>
</FileStats>
<SEC-Header>
0001654954-16-004900.hdr.sgml : 20161215
<ACCEPTANCE-DATETIME>20161215162629
ACCESSION NUMBER:		0001654954-16-004900
CONFORMED SUBMISSION TYPE:	10-Q/A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160630
FILED AS OF DATE:		20161215
DATE AS OF CHANGE:		20161215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FLUOROPHARMA MEDICAL, INC.
		CENTRAL INDEX KEY:			0001402785
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				208325616
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-147193
		FILM NUMBER:		162053949

	BUSINESS ADDRESS:	
		STREET 1:		8 HILLSIDE AVENUE
		STREET 2:		SUITE 207
		CITY:			MONTCLAIR
		STATE:			NJ
		ZIP:			07042
		BUSINESS PHONE:		973-744-1565

	MAIL ADDRESS:	
		STREET 1:		8 HILLSIDE AVENUE
		STREET 2:		SUITE 207
		CITY:			MONTCLAIR
		STATE:			NJ
		ZIP:			07042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Commercial E-Waste Management Inc
		DATE OF NAME CHANGE:	20070612

</SEC-Header>
</Header>

 0001654954-16-004900.txt : 20161215

10-Q/A
 1
 fpmi10qa_jun302016.htm
 FORM 10-Q/A

SEC Connect 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 10-Q/A 

(Mark One) 

For the transition period from __________ to
__________ 

Commission file number:  333-147193 

FluoroPharma Medical,
Inc.  

(Exact name of registrant as specified in its charter) 

Nevada  

20-8325616  

(State or other jurisdiction of incorporation or
organization) 

(I.R.S. Employer Identification No.) 

(973) 744-1565 

(Registrant s telephone number, including area
code) 

(Former name, former address and former fiscal year, if changed
since last report) 

Indicate by check mark whether the registrant (1) has filed reports
required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for
the past 90 days.  Yes [X]   No [  
] 

Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T during the preceding 12 months (or
such shorter period that the registrant was required to submit and
post such files.  Yes [X]   No [  
] 

Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
or a smaller reporting company. See the definitions of  large
accelerated filer ,  accelerated filer  and
 smaller reporting company  in Rule 12b-2 of the
Exchange Act. 

Large accelerated filer 

[   ] 

Accelerated filer 

[   ] 

Non-accelerated filer 

[   ] 

Smaller reporting company 

[X] 

Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).  Yes
[   ]   No [X] 

As of August 14, 2016, there were 33,756,772 shares of
$0.001 par value common stock issued and outstanding. 

Table of Contents  

FORM 10-Q 

FluoroPharma Medical, Inc. 

I NDEX 

Page 

Explanatory
Note   

2 

PART II  - OTHER INFORMATION 

Item
6. Exhibits  

2 

Signatures  

3 

Exhibit Index  

4 

-i- 

Table of Contents  

EXPLANATORY
 N OTE 

This
amended quarterly report on Form 10-Q/A is being filed solely for
the purpose of notating that confidential treatment was requested
as to certain portions of Exhibit 10.1 and 10.2 in connection with
a pending application for confidential treatment. Exhibit 10.1 and
10.2 were originally filed with FluoroPharma Medical, Inc. s
quarterly report on Form 10-Q on August 15, 2016 with certain
redactions. FluoroPharma Medical, Inc. has made no further change
to the previously filed quarterly report. 

-1- 

Table of Contents  

PART II - OTHER INFORMATION 

Item 6.   E xhibits 

Copies of the following documents are included as exhibits to this
report pursuant to Item 601 of Regulation S-K. 

* Pursuant to Rule 406T of Regulation S-T, these interactive data
files are deemed not filed or part of a registration statement or
prospectus for purposes of Sections 11 or 12 of the Securities Act
of 1933 or Section 18 of the Securities Exchange Act of 1934 and
otherwise are not subject to liability. 

** Previously filed and Confidential Treatment requested as to
certain portions of this Exhibit. 

*** Previously filed. 

-2- 

Table of Contents  

S IGNATURES 

Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly
authorized. 

FluoroPharma Medical, Inc. 

Date:  December 15, 2016 

/s/ Thomas H. Tulip  

Thomas H. Tulip, Ph.D. 

President and Chief Executive Officer 

(Principal Executive Officer) 

Date: December 15, 2016 

/s/ Tamara Rhein  

Tamara Rhein 

Chief Financial Officer 

(Principal Financial and Accounting Officer) 

-3- 

Table of Contents  

EXHIBIT
 I NDEX 

* Pursuant to Rule 406T of Regulation S-T, these interactive data
files are deemed not filed or part of a registration statement or
prospectus for purposes of Sections 11 or 12 of the Securities Act
of 1933 or Section 18 of the Securities Exchange Act of 1934 and
otherwise are not subject to liability. 

** Previously filed and Confidential treatment requested as to
certain portions of this Exhibit 

*** Previously filed 

-4- 

<EX-31.1>
 2
 ex31-1.htm
 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002

SEC Connect 

Exhibit 31.1 

Certification Pursuant to pursuant to Rule 13a-14(a) or Rule
15d-14(a) 

of the Securities Exchange Act of 1934, as amended 

I, Thomas H. Tulip, certify that: 

1. 

I have reviewed this Quarterly Report on Form 10-Q of FluoroPharma
Medical, Inc. (the  Registrant ); 

2. 

Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading
with respect to the period covered by this report; 

3. 

Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in
all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the
periods presented in this report; 

4. 

The registrant's other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and
internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have: 

a) 

Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the
period in which this report is being prepared; 

b) 

Designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under
my supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles; 

c) 

Evaluated the effectiveness of the registrant's disclosure controls
and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of
the end of the period covered by this report based on such
evaluation; and 

d) 

Disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the
registrant's most recent fiscal quarter (the registrant's
fourth quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect,
the registrant s internal control over financial
reporting. 

5. 

The registrant's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over
financial reporting, to the registrant's auditors and the audit
committee of the registrant's board of directors (or persons
performing the equivalent functions): 

a) 

All significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record, process, summarize and report financial information;
and 

b) 

Any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's
internal control over financial reporting. 

/s/ Thomas H. Tulip  

Thomas H. Tulip, Ph.D. 

Chief Executive Officer 

(Principal Executive Officer) 

Date: December 15, 2016 

</EX-31.1>

<EX-31.2>
 3
 ex31-2.htm
 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002

SEC Connect 

Exhibit 31.2 

Certification Pursuant to pursuant to Rule 13a-14(a) or Rule
15d-14(a) 

of the Securities Exchange Act of 1934, as amended 

I, Tamara Rhein, certify that: 

1. 

I have reviewed this Quarterly Report on Form 10-Q of FluoroPharma
Medical, Inc. (the  Registrant ); 

2. 

Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading
with respect to the period covered by this report; 

3. 

Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in
all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the
periods presented in this report; 

4. 

The registrant's other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and
internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have: 

a) 

Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the
period in which this report is being prepared; 

b) 

Designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under
my supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles; 

c) 

Evaluated the effectiveness of the registrant's disclosure controls
and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of
the end of the period covered by this report based on such
evaluation; and 

d) 

Disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the
registrant's most recent fiscal quarter (the registrant's fourth
quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the
registrant s internal control over financial
reporting. 

5. 

The registrant's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over
financial reporting, to the registrant's auditors and the audit
committee of the registrant's board of directors (or persons
performing the equivalent functions): 

a) 

All significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record, process, summarize and report financial information;
and 

b) 

Any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's
internal control over financial reporting. 

/s/ Tamara Rhein  

Tamara Rhein 

Chief Financial Officer 

(Principal Financial and Accounting Officer) 

Date: December 15, 2016 

</EX-31.2>

